News &amp; Updates

There is no evidence to suggest that treatment with tranexamic acid (TXA) helps limit hematoma expansion in patients with intracerebral haemorrhage (ICH) associated with nonvitamin K antagonist oral anticoagulants (NOACs), according to a study.

Niraparib maintenance confers prolonged survival in advanced ovarian cancer

Maintenance therapy with niraparib appears to increase progression-free survival (PFS) in patients with advanced ovarian cancer, irrespective of postoperative residual disease or biomarker status, according to data from the phase III PRIME study.

27 Jul 2023

Nemolizumab relieves itch, clears skin in patients with prurigo nodularis

27 Jul 2023 by

Treatment with nemolizumab significantly improves itch and skin clearance in patients with prurigo nodularis compared with placebo, according to the phase III OLYMPIA 2 trial presented at WCD 2023.

Intravaginal medical device a promising standalone treatment for nonspecific vaginitis

In women with nonspecific vaginitis, treatment with a medical device that uses vaginal ovules not only helps alleviate symptoms but also works to restore the normal pH and reduce signs of vaginal inflammation, as reported in a study.

Intranasal vardenafil works faster than oral formulation for ED

Vardenafil (VDF), an effective treatment for erectile dysfunction, administered by an intranasal spray formulation achieves faster but similar plasma concentration with only about one-third dose relative to oral VDF tablet, according to a study.

26 Jul 2023

$Cilta-cel a new Soc for lenalidomide-refractory MM?$

Cilta-cel a new Soc for lenalidomide-refractory MM?

In patients with lenalidomide-refractory multiple myeloma (MM), a single infusion of ciltacabtagene autoleucel (cilta-cel), a dual-binding BCMA*-directed chimeric antigen receptor (CAR) T-cell therapy, improved progression-free survival (PFS) compared with standard of care** (SoC), according to the phase III CARTITUDE-4 trial.

26 Jul 2023

Donanemab puts brakes on Alzheimer’s disease progression

In the treatment of individuals with early symptomatic Alzheimer's disease and amyloid and tau pathology, the immunoglobulin G1 monoclonal antibody donanemab helps slow clinical progression, according to the results of the phase III TRAILBLAZER-ALZ 2 study.

26 Jul 2023

Redefining survival in 3L+ large B-cell lymphoma with axicabtagene ciloleucel

Singapore’s Health Sciences Authority recently approved axicabtagene ciloleucel (Yescarta) for the treatment of relapsed or refractory large B-cell lymphoma (LBCL) in adults after ≥2 lines of systemic therapy. Shedding light on this innovative therapy, Dr Matthew Frank, Assistant Professor of Medicine specializing in Blood and Marrow Transplantation and Cellular Therapy at Stanford University, Stanford, California, US, discussed landmark trial data, some real-world evidence, and their implications for patient selection and adverse event management during the Yescarta Commercial Launch in Singapore in May.

Add-on dupilumab cuts exacerbations in patients with COPD, type 2 inflammation

Add-on dupilumab significantly reduced moderate or severe exacerbations in patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation compared with placebo, according to the BOREAS trial.